Bionano Laboratories Announced The Publication Of The First Framework Paper For The Clinical Adoption And Implementation Of The Optical Genome Mapping Workflow For Hematological Malignancy Applications
Portfolio Pulse from Benzinga Newsdesk
Bionano Laboratories has announced the publication of a framework paper for the clinical adoption of Optical Genome Mapping (OGM) for hematological malignancy applications. The paper, co-authored by an international consortium of 18 cancer researchers, provides recommendations for laboratories on assay development, clinical validation, and more. Bionano's OGM-Dx™ HemeOne is an LDT developed based on this framework.
January 03, 2024 | 1:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bionano Laboratories' publication of a framework for OGM in hematological malignancies may boost confidence in its OGM-Dx™ HemeOne test, potentially increasing its adoption in clinical settings.
The publication of the framework paper is likely to have a positive impact on Bionano Laboratories as it establishes a guideline for the adoption of their OGM technology in clinical settings. This endorsement by an international consortium of researchers could lead to increased credibility and interest in their OGM-Dx™ HemeOne test, potentially resulting in higher sales and market penetration in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100